FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3159514559> ?p ?o ?g. }

• W3159514559 endingPage "2170" @default.
• W3159514559 startingPage "2170" @default.
• W3159514559 abstract "Purpose: To assess the efficacy and safety of bevacizumab plus erlotinib in patients with RMC. Methods: We retrospectively reviewed the records of patients with RMC treated with bevacizumab plus erlotinib at our institution. Results: Ten patients were included in the study. Two patients achieved a partial response (20%) and seven patients achieved stable disease (70%). Tumor burden was reduced in seven patients (70%) in total, and in three out of five patients (60%) that had received three or more prior therapies. The median progression-free survival (PFS) was 3.5 months (95% CI, 1.8–5.2). The median overall survival (OS) from bevacizumab plus erlotinib initiation was 7.3 months (95% CI, 0.73–13.8) and the median OS from diagnosis was 20.8 months (95% CI, 14.7–26.8). Bevacizumab plus erlotinib was well tolerated with no grade ≥4 adverse events and one grade 3 skin rash. Dose reduction was required in one patient (10%). Conclusions: Bevacizumab plus erlotinib is clinically active and well tolerated in heavily pre-treated patients with RMC and should be considered a viable salvage strategy for this lethal disease." @default.
• W3159514559 created "2021-05-10" @default.
• W3159514559 creator A5000076877 @default.
• W3159514559 creator A5007689146 @default.
• W3159514559 creator A5017490262 @default.
• W3159514559 creator A5017537551 @default.
• W3159514559 creator A5044684419 @default.
• W3159514559 creator A5046603458 @default.
• W3159514559 creator A5046740782 @default.
• W3159514559 creator A5056909405 @default.
• W3159514559 creator A5058115259 @default.
• W3159514559 creator A5070147032 @default.
• W3159514559 creator A5072226386 @default.
• W3159514559 creator A5073556374 @default.
• W3159514559 creator A5080220488 @default.
• W3159514559 creator A5081277836 @default.
• W3159514559 date "2021-04-30" @default.
• W3159514559 modified "2023-10-17" @default.
• W3159514559 title "Efficacy and Safety of Bevacizumab Plus Erlotinib in Patients with Renal Medullary Carcinoma" @default.
• W3159514559 cites W1964122947 @default.
• W3159514559 cites W2004056464 @default.
• W3159514559 cites W2019607817 @default.
• W3159514559 cites W2059747280 @default.
• W3159514559 cites W2101549029 @default.
• W3159514559 cites W2106578635 @default.
• W3159514559 cites W2143929280 @default.
• W3159514559 cites W2161130083 @default.
• W3159514559 cites W2551447972 @default.
• W3159514559 cites W2561801176 @default.
• W3159514559 cites W2794375114 @default.
• W3159514559 cites W2891539948 @default.
• W3159514559 cites W2916858576 @default.
• W3159514559 cites W2937391264 @default.
• W3159514559 cites W2963695239 @default.
• W3159514559 cites W2970931404 @default.
• W3159514559 cites W3023801326 @default.
• W3159514559 cites W3109157639 @default.
• W3159514559 cites W4244590756 @default.
• W3159514559 doi "https://doi.org/10.3390/cancers13092170" @default.
• W3159514559 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/8124338" @default.
• W3159514559 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/33946504" @default.
• W3159514559 hasPublicationYear "2021" @default.
• W3159514559 type Work @default.
• W3159514559 sameAs 3159514559 @default.
• W3159514559 citedByCount "13" @default.
• W3159514559 countsByYear W31595145592021 @default.
• W3159514559 countsByYear W31595145592022 @default.
• W3159514559 countsByYear W31595145592023 @default.
• W3159514559 crossrefType "journal-article" @default.
• W3159514559 hasAuthorship W3159514559A5000076877 @default.
• W3159514559 hasAuthorship W3159514559A5007689146 @default.
• W3159514559 hasAuthorship W3159514559A5017490262 @default.
• W3159514559 hasAuthorship W3159514559A5017537551 @default.
• W3159514559 hasAuthorship W3159514559A5044684419 @default.
• W3159514559 hasAuthorship W3159514559A5046603458 @default.
• W3159514559 hasAuthorship W3159514559A5046740782 @default.
• W3159514559 hasAuthorship W3159514559A5056909405 @default.
• W3159514559 hasAuthorship W3159514559A5058115259 @default.
• W3159514559 hasAuthorship W3159514559A5070147032 @default.
• W3159514559 hasAuthorship W3159514559A5072226386 @default.
• W3159514559 hasAuthorship W3159514559A5073556374 @default.
• W3159514559 hasAuthorship W3159514559A5080220488 @default.
• W3159514559 hasAuthorship W3159514559A5081277836 @default.
• W3159514559 hasBestOaLocation W31595145591 @default.
• W3159514559 hasConcept C121608353 @default.
• W3159514559 hasConcept C126322002 @default.
• W3159514559 hasConcept C141071460 @default.
• W3159514559 hasConcept C143998085 @default.
• W3159514559 hasConcept C197934379 @default.
• W3159514559 hasConcept C2776694085 @default.
• W3159514559 hasConcept C2777802072 @default.
• W3159514559 hasConcept C2778087573 @default.
• W3159514559 hasConcept C2778570526 @default.
• W3159514559 hasConcept C2779438470 @default.
• W3159514559 hasConcept C2909325608 @default.
• W3159514559 hasConcept C71924100 @default.
• W3159514559 hasConceptScore W3159514559C121608353 @default.
• W3159514559 hasConceptScore W3159514559C126322002 @default.
• W3159514559 hasConceptScore W3159514559C141071460 @default.
• W3159514559 hasConceptScore W3159514559C143998085 @default.
• W3159514559 hasConceptScore W3159514559C197934379 @default.
• W3159514559 hasConceptScore W3159514559C2776694085 @default.
• W3159514559 hasConceptScore W3159514559C2777802072 @default.
• W3159514559 hasConceptScore W3159514559C2778087573 @default.
• W3159514559 hasConceptScore W3159514559C2778570526 @default.
• W3159514559 hasConceptScore W3159514559C2779438470 @default.
• W3159514559 hasConceptScore W3159514559C2909325608 @default.
• W3159514559 hasConceptScore W3159514559C71924100 @default.
• W3159514559 hasFunder F4320306078 @default.
• W3159514559 hasFunder F4320307324 @default.
• W3159514559 hasFunder F4320308982 @default.
• W3159514559 hasFunder F4320332521 @default.
• W3159514559 hasFunder F4320337351 @default.
• W3159514559 hasIssue "9" @default.
• W3159514559 hasLocation W31595145591 @default.
• W3159514559 hasLocation W31595145592 @default.
• W3159514559 hasLocation W31595145593 @default.
• W3159514559 hasLocation W31595145594 @default.

• next